Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%.

Shares of Akero ascended by 115% in early Monday trading upon the news. MASH-associated cirrhosis patients “face a poor prognosis,” Catriona Yale, chief development officer at Akero, said on an ...